Researchers from Marseille in France have reported a 76% 2-year, leukemia-free survival in 33 adults (median age of 52 years; oldest 60 years) with acute myeloid leukemia (AML) and treated with a reduced-intensity allogeneic stem cell transplant研究者從馬賽，在法國已經報告了76 ％ ，年期為2年，早幼粒細胞白血病-自由生存在33個成人（年齡中位數為52年;最年長60歲）與急性髓細胞性白血病（ AML ）和治療降低強度異基因造血幹細胞移植 ? ？ after remission induction and consolidation.減免後，誘導和鞏固。

The details of this phase II study appeared in the November 1, 2005, issue of Cancer .詳細情況II期研究出現在2005年11月1日，發行的癌症。

The role of allogeneic stem cell transplantation in the treatment of younger patients with AML who relapse is well established.角色的異基因造血幹細胞移植治療的年輕患者與反洗錢復吸者，是早已確立。 However, the role of allogeneic stem cell transplantation in patients in first remission is still evolving.不過，這一作用的異基因造血幹細胞移植的患者在第一次緩解仍在演變之中。 Current data suggests that young patients with intermediate risk factors benefit from an allogeneic stem cell transplant in first remission while good risk and poor risk patients do not.目前的數據表明，年輕病人中間的危險因素有利於從異基因造血幹細胞移植，在第一次減刑，而良好的風險和風險患者沒有這樣的規定。 For good risk patients the best strategy is to transplant only those patients who relapse.良好的高危病人最好的策略是只移植的病人復發。 For poor risk patients there has been no improvement in outcome over the past 3 decades with or without a transplant.為貧困高危病人一直存在，並沒有改善的結果，在過去30年來，無論有沒有移植。 This is especially true for older patients who have more aggressive disease and often have significant co-morbidities interfering with optimal aggressive therapy.這一點尤其適用於老年患者，他們有更積極的疾病，而且往往有顯著的合作病痛干擾最優積極治療。

Sixty-four percent of 33 patients (median age 52 years) in study were characterized as high risk for relapse. 64 ％的33例（中位數年齡52歲）在研究人的特點是高風險，為復發。 All patients had achieved a complete remission to induction therapy and had received two consolidation chemotherapy courses.所有患者取得了完全緩解，以誘導治療，並獲得了兩項合併化療課程。 Thirteen patients also received an autologous stem transplant following high-dose melphalan treatment. 13名病人還收到了自體造血幹移植後，高劑量馬法蘭治療。 Transplant-related mortality was 9% and 18% relapsed.移植相關死亡率為9 ％和18 ％復發。 With a median follow-up of 18 months 26 patients survive and 24 of these have not relapsed.與隨訪18個月的26例患者存活24件，這些都沒有復發。 No patient with chronic graft-versus host disease (GVHD) had a relapse while 44% without chronic GVHD relapsed.無1例慢性移植物抗宿主病（ GVHD的）已復發，而44 ％的慢性移植物抗宿主病復發。

These data suggests that immunotherapy in the form of a reduced-intensity allogeneic stem cell transplant can be used to eradicate minimal residual disease in patients with AML with acceptable toxicity.這些數據表明，在免疫療法的形式，減少了強度異基因造血幹細胞移植可用於消除微小殘留病的患者反洗錢與可接受的毒性。

Link鏈接
Reference: Blaise DP, Briron JM, Faucher C, et al.參考：布萊斯的DP ， briron jm ， faucher c ，等。 Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as first-line treatment.降低強度調節之前，異基因造血幹細胞移植治療急性髓細胞白血病，作為第一線治療。 Cancer .癌症。 2005;104:1931-1938. 2005年; 104:1931-1938 。

Note:注：
? ？ Allogeneic stem cell transplants refer to stem cells that are taken from one person and given to another. 異基因造血幹細胞移植是指幹細胞是取自一人，由於到另一個地方。 With these transplants, the donor’s cells must match the recipient’s tissue type (much like a blood transfusion needing to match the blood type of the person receiving it).這些移植手術，捐贈者的細胞要符合受援國的組織型（很像一支輸血需要，以配合血型的人接受它） 。

In many cases, the stem cell donor is related to the recipient, like a brother or sister.在許多情況下，造血幹細胞捐贈者是與受贈人，像一個兄弟或姐妹。 However, stem cells from unrelated donors can be used if the tissue types matches.但是，幹細胞無關的捐助者，可用於如組織各類比賽。 It may also be possible to use cells from banked cord blood.它也可以盡量利用細胞庫的臍帶血。